Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
An announcement from Somnomed Limited ( (AU:SOM) ) is now available.
SomnoMed Limited reported a strong financial performance for FY25, with a 21.6% increase in revenue to $111.5 million, surpassing market guidance. The company achieved significant milestones, including treating one million patients and expanding its facility capacity to support future growth. The North American and European markets were key contributors to this success, with Europe remaining the largest revenue-generating region. The company’s strategic focus on increasing capacity and reducing backlog positions it well for sustained growth and value delivery.
The most recent analyst rating on (AU:SOM) stock is a Buy with a A$1.00 price target. To see the full list of analyst forecasts on Somnomed Limited stock, see the AU:SOM Stock Forecast page.
More about Somnomed Limited
SomnoMed Limited is a leading provider of oral appliance treatment solutions for sleep-related breathing disorders and obstructive sleep apnea. The company focuses on delivering innovative solutions to improve patient outcomes in the sleep health industry.
Average Trading Volume: 65,479
Technical Sentiment Signal: Hold
Current Market Cap: A$159.3M
See more insights into SOM stock on TipRanks’ Stock Analysis page.